Cocrystal Pharma to Present at H.C. Wainwright Virtual BioConnect Conference
05 janv. 2021 08h00 HE
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel...
Provectus Biopharmaceuticals Announces Change to Board of Directors
16 juil. 2020 08h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, July 16, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today is pleased to announce the addition of Webster Bailey to the Company's Board of Directors (the “Board”), effective as...
Provectus Announces Acceptance of PV-10® Liver Cancer Abstracts at American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program
29 avr. 2020 16h30 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, April 29, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today is pleased to announce that abstracts about and data from our clinical trials of investigational autolytic cancer...
Provectus Biopharmaceuticals Announces Acceptances of PV-10 Poster Presentations at American Society of Clinical Oncology (ASCO) Annual Meeting
17 avr. 2019 16h05 HE
|
Provectus Biopharmaceuticals Inc.
Metastatic neuroendocrine tumors; Advanced cutaneous melanomaIntratumoral administration of PV-10 to visceral and superficial disease locationsSingle-agent and combination therapy treatment settings ...
ConSynance Joins the Prader-Willi Syndrome Clinical Trial Consortium
11 mars 2019 09h00 HE
|
ConSynance Therapeutics, Inc.
Rensselaer, New York., March 11, 2019 (GLOBE NEWSWIRE) -- ConSynance Therapeutics, Inc., a clinical-stage biotechnology company developing two innovative treatments for Prader-Willi Syndrome (PWS),...
INmune Bio Co-Founders to Present at World Immunotherapy Congress during the Festival of Biologics San Diego
26 févr. 2019 09h30 HE
|
INmune Bio, Inc.
Presentations to address the role of the innate immune system in treating cancer LA JOLLA, Calif., Feb. 26, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused...
INmune Bio Awarded a $1 Million Grant for the Development of XPro1595 for the treatment of Alzheimer’s Disease
11 févr. 2019 08h00 HE
|
INmune Bio, Inc.
The Alzheimer’s Association awarded INmune Bio the Part the Cloud to RESCUE grant to target neuroinflammation in Alzheimer’s Disease LA JOLLA, Calif., Feb. 11, 2019 (GLOBE NEWSWIRE) -- INmune...
INmune Bio, Inc. Announces Pricing of Initial Public Offering
15 janv. 2019 15h00 HE
|
INmune Bio, Inc.
LA JOLLA, CA, Jan. 15, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (“INmune” or the “Company”), an immunotherapy company focused on developing therapies that harness the patient’s innate immune...
INmune Bio Granted Phase I Clinical Trial Authorization of Lead Product INKmune™ in Refractory and Recurrent Ovarian Cancer Patients
19 déc. 2018 08h00 HE
|
INmune Bio, Inc.
LA JOLLA, California, Dec. 19, 2018 (GLOBE NEWSWIRE) -- INmune Bio Inc., an immunotherapy company developing treatments to reprogram the innate immune system to fight disease, announced today that...
Trastuzumab-Resistant HER2 Positive Breast Cancer Reversed By Treatment with INB03
11 déc. 2018 08h30 HE
|
INmune Bio, Inc.
Study Results Presented at San Antonio Breast Cancer Symposium 2018 LA JOLLA, Calif., Dec. 11, 2018 (GLOBE NEWSWIRE) -- INmune Bio, Inc., an immunotherapy company developing treatments to...